Compare Quest Diagnostics Inc (DGX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Quest Diagnostics Inc trades at $202.51 (market cap $22.80B), while Vanguard International High Dividend Yield ETF trades at $101.51. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | VYMI | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $101.60 |
52-Week Low | $166.42 | $79.76 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
VYMI trades at $100.06, down 0.51% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on international high-dividend stocks, offering diversification and a low 0.07% expense ratio. Recent news highlights its role in hedging against U.S. market concentration and stagflation risks, with strong dividend growth over the past three years.
Outlook remains positive due to attractive international valuations and dividend yield near 4%, though risks include currency fluctuations and global economic slowdowns. Analyst sentiment is favorable, emphasizing long-term growth potential versus U.S. equities, but investors should monitor geopolitical and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
